Antibacterial drugs launched from January 2013 to December 2022
bacterial infections
BACTERIAL INFECTIONS
In the last 10 years, 19 new small molecule antibacterial drugs (eight NP-derived and 11 synthetic-derived) and four new BL/BLI combinations have been approved (Table Since the 2019 review [Levonadifloxacin (Contezolid (Three non-traditional antibacterial drugs (two mAbs and one biotherapeutic) were launched between 2013 and 2022 to treat bacterial infections (Table Obiltoxaximab [In November 2022, a live biotherapeutic product, RBX2660 (Rebyota), was approved by the US FDA [Although outside the cut-off period, another non-traditional antibacterial product, Vowst (SER-109), developed by Seres Therapeutics Inc (Cambridge, MA, USA) and Nestlé Health Science (Hoboken, NJ, USA) was approved by the US FDA on 26 April 2023.